Condition: Autoimmunity · Cancer · Immunotoxicity · Sponsor: Abramson Cancer Center at Penn Medicine
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
This description comes directly from the study's public registry record.
Kyra J Sacksith · 215-898-9339 · kyra.sacksith@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Pennsylvania - Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04119713